165 related articles for article (PubMed ID: 21709193)
1. Immunotherapy for glioblastoma: the devil is in the details.
Lesniak MS
J Clin Oncol; 2011 Aug; 29(22):3105; author reply 3105-6. PubMed ID: 21709193
[No Abstract] [Full Text] [Related]
2. Adjuvant temozolomide: how long and how much?
Franceschi E; Tosoni A; Brandes AA
Expert Rev Anticancer Ther; 2008 May; 8(5):663-5. PubMed ID: 18471038
[No Abstract] [Full Text] [Related]
3. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
[TBL] [Abstract][Full Text] [Related]
4. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Cahill DP; Codd PJ; Batchelor TT; Curry WT; Louis DN
Clin Neurosurg; 2008; 55():165-71. PubMed ID: 19248684
[No Abstract] [Full Text] [Related]
5. [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
Malkoun N; Fotso MJ; Cartier L; Forest F; Auberdiac P; Chargari C; Thorin J; Pacaut C; Peoc'h M; Nuti C; Schmitt T; Magné N
Cancer Radiother; 2011 Jun; 15(3):202-7. PubMed ID: 21450506
[TBL] [Abstract][Full Text] [Related]
6. [Side effects of temozolomide treatment in patient with glioblastoma multiforme--case study].
Łata S; Molczyk A
Przegl Lek; 2010; 67(5):445-6. PubMed ID: 20684359
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
[TBL] [Abstract][Full Text] [Related]
8. Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Stuplich M; Hadizadeh DR; Kuchelmeister K; Scorzin J; Filss C; Langen KJ; Schäfer N; Mack F; Schüller H; Simon M; Glas M; Pietsch T; Urbach H; Herrlinger U
J Clin Oncol; 2012 Jul; 30(21):e180-3. PubMed ID: 22689800
[No Abstract] [Full Text] [Related]
9. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
10. Treatment of newly diagnosed glioblastoma multiforme.
Nieder C
J Clin Oncol; 2002 Jul; 20(14):3179-80; author reply 3181-2. PubMed ID: 12118034
[No Abstract] [Full Text] [Related]
11. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Wen PY
J Clin Oncol; 2010 Apr; 28(12):1977-9. PubMed ID: 20308652
[No Abstract] [Full Text] [Related]
12. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
13. Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Stupp R; Hottinger AF; van den Bent MJ; Dietrich PY; Brandes AA
Ann Oncol; 2008 Sep; 19 Suppl 7():vii209-16. PubMed ID: 18790951
[No Abstract] [Full Text] [Related]
14. Treatment of brain tumors.
Ashby L; LaRocca R; Ryken T
N Engl J Med; 2005 Jun; 352(22):2350-3; author reply 2350-3. PubMed ID: 15938013
[No Abstract] [Full Text] [Related]
15. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
Chamberlain MC; Glantz MJ; Chalmers L; Van Horn A; Sloan AE
J Neurooncol; 2007 Mar; 82(1):81-3. PubMed ID: 16944309
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
[TBL] [Abstract][Full Text] [Related]
17. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Gerstein J; Franz K; Steinbach JP; Seifert V; Fraunholz I; Weiss C; Rödel C
Radiother Oncol; 2010 Dec; 97(3):382-6. PubMed ID: 20850883
[TBL] [Abstract][Full Text] [Related]
18. Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma.
Hamilton DA
Cancer Treat Rev; 2006 Oct; 32(6):483-6. PubMed ID: 16730911
[No Abstract] [Full Text] [Related]
19. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
Li L; Quang TS; Gracely EJ; Kim JH; Emrich JG; Yaeger TE; Jenrette JM; Cohen SC; Black P; Brady LW
J Neurosurg; 2010 Aug; 113(2):192-8. PubMed ID: 20345222
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Neyns B; Hoorens A; Stupp R
Acta Neurol Belg; 2008 Dec; 108(4):131-4. PubMed ID: 19239041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
